113 related articles for article (PubMed ID: 7160922)
21. All that is hypogonadal in haemochromatosis is not due to iron deposition.
O'Sullivan EP; McDermott JH; Howel Walsh C
Ir J Med Sci; 2007 Mar; 176(1):45-7. PubMed ID: 17849524
[TBL] [Abstract][Full Text] [Related]
22. Osteoporosis in male hypogonadism: responses to androgen substitution differ among men with primary and secondary hypogonadism.
Schubert M; Bullmann C; Minnemann T; Reiners C; Krone W; Jockenhövel F
Horm Res; 2003; 60(1):21-8. PubMed ID: 12792150
[TBL] [Abstract][Full Text] [Related]
23. Reversibility of hypogonadotrophic hypogonadism associated with genetic haemochromatosis.
Cundy T; Butler J; Bomford A; Williams R
Clin Endocrinol (Oxf); 1993 Jun; 38(6):617-20. PubMed ID: 8334747
[TBL] [Abstract][Full Text] [Related]
24. Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7-10 years.
Behre HM; von Eckardstein S; Kliesch S; Nieschlag E
Clin Endocrinol (Oxf); 1999 May; 50(5):629-35. PubMed ID: 10468929
[TBL] [Abstract][Full Text] [Related]
25. Testosterone 5alpha-reduction in the skin of normal subjects and of patients with abnormal sex development.
Kuttenn F; Mauvais-Jarvis P
Acta Endocrinol (Copenh); 1975 May; 79(1):164-76. PubMed ID: 1173304
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of spermatogenesis in men using various combinations of oral progestagens and percutaneous or oral androgens.
Guerin JF; Rollet J
Int J Androl; 1988 Jun; 11(3):187-99. PubMed ID: 2970439
[TBL] [Abstract][Full Text] [Related]
27. [Hypogonadism in idiopathic hemochromatosis].
Foscolo G; De Menis E; Legovini P; Breda F; Monco A; Scaldaferri E; Conte N
Minerva Endocrinol; 1989; 14(3):159-63. PubMed ID: 2516238
[TBL] [Abstract][Full Text] [Related]
28. Long-term effects of dihydrotestosterone treatment on prostate growth in healthy, middle-aged men without prostate disease: a randomized, placebo-controlled trial.
Idan A; Griffiths KA; Harwood DT; Seibel MJ; Turner L; Conway AJ; Handelsman DJ
Ann Intern Med; 2010 Nov; 153(10):621-32. PubMed ID: 21079217
[TBL] [Abstract][Full Text] [Related]
29. Monoamines and neurosteroids in sexual function during induced hypogonadism in healthy men.
Bloch M; Rubinow DR; Berlin K; Kevala KR; Kim HY; Schmidt PJ
Arch Gen Psychiatry; 2006 Apr; 63(4):450-6. PubMed ID: 16585475
[TBL] [Abstract][Full Text] [Related]
30. Plasma levels of dihydrotestosterone remain in the normal range in men treated with long-acting parenteral testosterone undecanoate.
Yassin AA; Saad F
Andrologia; 2007 Oct; 39(5):181-4. PubMed ID: 17714216
[TBL] [Abstract][Full Text] [Related]
31. Delta-4-androstene-3,17-dione binds androgen receptor, promotes myogenesis in vitro, and increases serum testosterone levels, fat-free mass, and muscle strength in hypogonadal men.
Jasuja R; Ramaraj P; Mac RP; Singh AB; Storer TW; Artaza J; Miller A; Singh R; Taylor WE; Lee ML; Davidson T; Sinha-Hikim I; Gonzalez-Cadavid N; Bhasin S
J Clin Endocrinol Metab; 2005 Feb; 90(2):855-63. PubMed ID: 15522925
[TBL] [Abstract][Full Text] [Related]
32. Microphallus: eventual phallic size is dependent on the timing of androgen administration.
Husmann DA; Cain MP
J Urol; 1994 Aug; 152(2 Pt 2):734-9. PubMed ID: 8022007
[TBL] [Abstract][Full Text] [Related]
33. A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency.
Ly LP; Jimenez M; Zhuang TN; Celermajer DS; Conway AJ; Handelsman DJ
J Clin Endocrinol Metab; 2001 Sep; 86(9):4078-88. PubMed ID: 11549629
[TBL] [Abstract][Full Text] [Related]
34. Concentrations of unconjugated 5 alpha-androstane-3 alpha, 17 beta-diol and 5 alpha-androstane-3 beta, 17 beta-diol and their precursor in human testicular tissue. Comparison with testosterone, 5 alpha-dihydrotestosterone, estradiol-17 beta, and with steroid concentrations in human epididymis.
Tamm J; Volkwein U; Kurniawan E; Becker H
J Steroid Biochem; 1987 Mar; 26(3):345-8. PubMed ID: 3586650
[TBL] [Abstract][Full Text] [Related]
35. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men--a clinical research center study.
Wang C; Eyre DR; Clark R; Kleinberg D; Newman C; Iranmanesh A; Veldhuis J; Dudley RE; Berman N; Davidson T; Barstow TJ; Sinow R; Alexander G; Swerdloff RS
J Clin Endocrinol Metab; 1996 Oct; 81(10):3654-62. PubMed ID: 8855818
[TBL] [Abstract][Full Text] [Related]
36. Androgen levels and sex functions in testosterone-treated hypogonadal men.
Gooren LJ
Arch Sex Behav; 1987 Dec; 16(6):463-73. PubMed ID: 3426390
[TBL] [Abstract][Full Text] [Related]
37. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. III. Higher 5 alpha-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone.
Anderson RA; Wallace AM; Wu FC
J Clin Endocrinol Metab; 1996 Mar; 81(3):902-8. PubMed ID: 8772548
[TBL] [Abstract][Full Text] [Related]
38. Osteoporosis in hemochromatosis: iron excess, gonadal deficiency, or other factors?
Diamond T; Stiel D; Posen S
Ann Intern Med; 1989 Mar; 110(6):430-6. PubMed ID: 2919850
[TBL] [Abstract][Full Text] [Related]
39. Androgen treatment of middle-aged, obese men: effects on metabolism, muscle and adipose tissues.
Mårin P; Krotkiewski M; Björntorp P
Eur J Med; 1992 Oct; 1(6):329-36. PubMed ID: 1341460
[TBL] [Abstract][Full Text] [Related]
40. Hypogonadotropic hypogonadism in idiopathic hemochromatosis: evidence for combined hypothalamic and pituitary involvement.
Siminoski K; D'Costa M; Walfish PG
J Endocrinol Invest; 1990 Nov; 13(10):849-53. PubMed ID: 2128941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
